论文部分内容阅读
目的探讨丹参酮ⅡA磺酸钠联合依那普利对慢性肺源性心脏病急性加重期患者血液流变学和心肺功能的影响。方法将2012年10月至2014年4月我院收治的慢性肺心病急性加重患者92例分为治疗组和对照组各46例,两组均在常规治疗的基础上应用依那普利治疗,治疗组加用丹参酮ⅡA磺酸钠注射液治疗。结果治疗后,治疗组总有效率为91.3%,明显优于对照组76.1%的总有效率;两组患者的血气分析指标、血流动力学指标及肺动脉收缩压等均较治疗前有明显改善,而且治疗组较对照组改善更为显著,差异有统计学意义(P<0.05);两组不良反应轻微。结论慢性肺心病急性加重期患者应用丹参酮ⅡA磺酸钠与依那普利联合治疗,临床效果显著,安全可靠。
Objective To investigate the effects of sodium tanshinone Ⅱ A sulfonate and enalapril on the hemorheology and cardiopulmonary function in patients with acute exacerbation of chronic cor pulmonale. Methods From October 2012 to April 2014, 92 patients with acute exacerbation of chronic pulmonary heart disease admitted to our hospital were divided into treatment group (46 cases) and control group (46 cases). Both groups were treated with enalapril on the basis of routine treatment, Treatment group with tanshinone Ⅱ A sodium sulfonate treatment. Results After treatment, the total effective rate was 91.3% in the treatment group, which was significantly better than 76.1% in the control group. The blood gas analysis indexes, hemodynamic indexes and pulmonary artery systolic pressure were significantly improved in both groups , And the treatment group improved more significantly than the control group, the difference was statistically significant (P <0.05); two groups of mild adverse reactions. Conclusion In patients with acute exacerbation of chronic pulmonary heart disease, the combination of tanshinone Ⅱ A sulfonate and enalapril has a significant clinical effect and is safe and reliable.